Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Triple Negative Breast Cancer
Phase PHASE1
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase Ib trial tests the safety, side effects and best dose of anti-HLA-A2/NY-ESO-1 T-cell receptor (TCR)-transduced autologous T lymphocytes (A2-ESO-1 TCR-T cells) in treating patients with NY-ESO-1 overexpression positive triple negative breast cancer (TNBC) that has come back after a period of improvement (relapsed/recurrent) or that does not respond to treatment (refractory), and that may have spread from where it first started (primary site) to nearby tissue, lymph nodes (advanced) or to other places in the body (metastatic). NY-ESO-1 is an antigen found on the surface of many different types of tumor cells including TNBC. Antigens make it possible for immune cells to recognize and kill germ cells that invade the body, however, it is more difficult for immune cells to recognize antigens on tumor cells. T cells are a special type of immune cell in the blood. These T cells may be trained to recognize the NY-ESO-1 antigen on tumor cells, allowing the T cells to attack and kill those tumor cells. The A2-ESO-1 TCR-T cells are T cells that have been removed from the patient's blood through a process called leukapheresis and then changed in the laboratory to recognize NY-ESO-1 on tumor cells. When given back to the patient, these A2-ESO-1 TCR-T cells find and attack tumor cells that express NY-ESO-1. Chemotherapy drugs, such as cyclophosphamide and fludarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. They are given before the T cells to support optimum activity of the A2-ESO-1 TCR-T cells. IL-2 (aldesleukin) is in a class of drugs known as cytokines. It is a man-made version of a naturally occurring protein that stimulates the body to produce other chemicals which increase the body's ability to fight cancer. A2-ESO-1 TCR-T cells may kill more tumor cells in patients with recurrent or refractory advanced or metastatic TNBC that overexpresses NY-ESO-1.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Aldesleukin — Given IV
  • Biological: Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes — Given IV
  • Procedure: Biopsy — Undergo biopsy of breast tumor
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Computed Tomography — Undergo CT scan
  • Drug: Cyclophosphamide — Given IV
  • Procedure: Echocardiography — Undergo ECHO
  • Drug: Fludarabine — Given IV

Primary Outcomes

  • Maximum tolerated dose (MTD) of anti-HLA-A2/NY-ESO-1 T-cell receptor (TCR)-transduced autologous T lymphocytes (A2-ESO-1 TCR-engineered T cells) (Up to 6 weeks after A2-ESO-1 TCR-engineered T cell infusion)
  • Incidence of dose-limiting toxicities (Up to 6 weeks after A2 ESO-1 TCR-engineered T cell infusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-12-17
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Daphne Stewart, MD (PRINCIPAL_INVESTIGATOR) - University of Southern California
Contact Information
Study Contact:
Kimberly Arieli, RN
323-865-3935
Kimberly.Arieli@med.usc.edu
Kimberly Arieli, RN
323-865-0451
Kimberly.Arieli@med.usc.edu
USC / Norris Comprehensive Cancer Center
Daphne Stewart, MD
USC / Norris Comprehensive Cancer Center
Interventions
  • Biological: Aldesleukin — Given IV
  • Biological: Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes — Given IV
  • Procedure: Biopsy — Undergo biopsy of breast tumor
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Computed Tomography — Undergo CT scan
Study Locations (1 sites)
USC / Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States
Eligibility Criteria
Inclusion Criteria: * Female aged \>= 18 years * Histologically confirmed advanced or metastatic TNBC that have relapsed on or are refractory to 2 or more lines of standard-of-care therapy. TNBC is defined as estrogen receptor (ER) and progesterone receptor negative (\< 10% immunohistochemistry \[IHC\] staining) and HER2 negative (IHC 1+ or 0 AND/OR in situ hybridization negative based on: * Single-probe average HER2 copy number \< 4.0 signals/cell * Dual-probe HER2/CEP17 ratio \< 2.0 with an average HER2 copy number \< 4.0 signals/cell) * HLA-A2+ and tumoral overexpression of NY-ESO-1 (2 to 3+ IHC staining in \> 50% of cells) * Have measurable disease based on RECIST 1.1 * Life expectancy \>= 6 months * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Hemoglobin \>= 9.0 g/dL (transfusions permitted) * Absolute neutrophil count (ANC) \>= 1500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Creatinine (Cr) \< 2 x upper limit of normal (ULN), and Cr clearance (CrCl) \>= 50 mL/min by Cockcroft and Gault * Alanine transaminase (ALT) and aspartate transaminase (AST) \< 2 x ULN (Patients with liver metastases whose ALT/AST are \< 5 x ULN are eligible for enrollment) * Bilirubin \< 2 x ULN * Lymphocyte count \>= 500/uL * Cardiac left ventricular ejection fraction (LVEF) \>= 50% * Negative serum pregnancy (human chorionic gonadotropin \[beta-hCG\]) test within 7 days of leukapheresis for women of childbearing potential (WOCBP). WOCBP must be willing to use a highly effective method of contraception for the course of the study through 90 days after A2-ESO-1 TCR-engineered T cell infusion * Willing and able to provide written informed consent for the study * Willing to provide biopsy tissues and blood samples as required by the study Exclusion Criteria: * Radiation therapy, chemotherapy, or non-cytotoxic investigational agent within 2 weeks of leukapheresis * Received cyclophosphamide within the past 4 months * Evidence of New York Heart Association class III or greater cardiac disease * History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within the past 12 months * History of congenital QT prolongation * Absolute QT interval of \> 470 msec in the presence of \> 4.0 mEq/L potassium and \> 1.8 mg/dL magnesium * Brain or leptomeningeal metastases * Females who are pregnant or breastfeeding * Hypersensitivity or intolerance to cyclophosphamide, fludarabine, IL-2, or their components * History of clinically significant gastrointestinal bleeding, gastric or intestinal ulceration, or perforation within 6 months of enrollment. * Any severe and/or uncontrolled medical conditions or other conditions that could affect participation in the study, such as severely impaired lung function, any active (acute or chronic) or uncontrolled infection/disorders, and non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the study treatment * Current use of medications that interact with or compromise the immune system such as steroid doses \> 10 mg/day prednisone or equivalent daily within 2 weeks before leukapheresis * History of immunodeficiency disease or autoimmune disease, with exceptions such as Hashimoto's thyroiditis / hypothyroidism, or controlled Type 1 diabetes * Have any active and uncontrolled infection. * Active hepatitis B (as defined as positive hepBsAntigen or detectable hepatitis B DNA) or hepatitis C infection. Patients who are hepatitis B surface Antigen negative and have a negative hep B DNA are allowed. If hepatitis C antibody test is positive, then patients must be tested for the presence of antigen by RT-PCR and be HCV RNA negative. Patients with laboratory evidence of cleared hepatitis B or C infection may enroll. Patients with no prior history of hepatitis B infection who have been vaccinated against hepatitis B and who have a positive antibody against hepatitis B surface antigen as the only evidence of prior exposure may enroll. Patients with a history of hepatitis C infection may be eligible if they have completed antiviral treatment and show no detectable HCV RNA for 6 months prior to enrollment. * Human immunodeficiency virus (HIV) infection or seropositive for HIV antigens * Concurrent use of any complementary or alternative medicines * Unwilling or unable to comply with the study protocol * Prior major surgery that requires general anesthesia must be completed at least 4 weeks before leukapheresis and surgery that requires local anesthesia (except for study tissue sample collection) must be completed at least 2 weeks before leukapheresis and surgery that requires local anesthesia (except for study tissue sample collection) must be completed at least 2 weeks before leukapheresis
Conditions Depression
Phase NA
Enrollment 196
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized controlled trial is to address which treatment strategy (continue right unilateral (RUL) ECT or switch to bitemporal (BT) ECT speeds up recovery and has the least impact on memory function, in case of early non-response during an acute course of ECT for difficult-to-treat depression. The main questions it aims to answer are: * Assess the antidepressant efficacy and cognitive impact of the continuation of an ongoing treatment with RUL ECT compared to switching the treatment technique to BT ECT, in patients failing to show an early response to an acute course of ECT for major depression; * Assess group and subject-specific trajectories of depressive symptom severity and neurocognitive performance during the acute ECT course and up to 3 months post-treatment. Participants treated with ECT for depression, showing no 'response' (≥50 percent decrease in depressive symptom severity compared to baseline) after 4 treatment sessions, will be randomized to either switch to BT ECT or continue with RUL ECT. Mood and neurocognitive assessments will be performed at baseline, after 4 ECT sessions (before randomization), after 8 ECT sessions, at the end of the acute course and 3 month after the acute course.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: switch to BT electrode position — use of different electrode positions of ECT device
  • Device: continue with RUL electrode position — use of different electrode positions of ECT device

Primary Outcomes

  • Change form baseline Depressive Symptom Severity (after 4 ECT sessions (2 weeks))
  • Change form baseline Depressive Symptom Severity (after 8 ECT sessions (4 weeks))
  • Depressive Symptom Severity (at the end of acute ECT course (up to 7 weeks))
  • Depressive Symptom Severity (3 months post-acute course)
  • Autobiographical Memory (after 4 ECT sessions (2 weeks))
  • Autobiographical Memory (after 8 ECT sessions (4 weeks))
  • Autobiographical Memory (at the end of acute ECT course (up to 7 weeks))
  • Autobiographical Memory (3 months post-acute course)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-01
Completion: 2026-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 196 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitaire Ziekenhuizen KU Leuven
Collaborators: Universiteit Antwerpen, AZ Sint-Jan AV, General Hospital Groeninge
Principal Investigators:
  • Pascal Sienaert, MD, PhD (PRINCIPAL_INVESTIGATOR) - UPC KU Leuven
Contact Information
Study Contact:
Pascal Sienaert, MD,PhD
+322 758 05 11
pascal.sienaert@upckuleuven.be
Pascal Sienaert, MD, PhD
UPC Kortenberg
Interventions
  • Device: switch to BT electrode position — use of different electrode positions of ECT device
  • Device: continue with RUL electrode position — use of different electrode positions of ECT device
Study Locations (1 sites)
UPC Kortenberg, Kortenberg, Belgium
Eligibility Criteria
Inclusion Criteria: * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures * Age 18 or older * Diagnosis of major depressive disorder (DSM-5 296.21-30) or bipolar disorder, depressed (DSM-5 296.51-54; 296.84). Exclusion Criteria: * Contra-indication for general anesthesia * Non-Dutch speaking * Diagnosis of schizoaffective disorder or schizophrenia * Diagnosis of substance use disorder in the past six months * Diagnosis of neurocognitive disorder or intellectual disability alongside a MoCA score \<23 * Previous ECT course in the past three months * Participation in an interventional Trial with an investigational medicinal product or device * Pregnancy
Conditions Lymphedema, Breast Cancer
Phase NA
Enrollment 280
Locations 36 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to test whether lymphatic surgery provides better QoL (assessed with the Lymph-ICF-UL, (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema)) 15 months after randomization (and therefore about one year after surgery) compared to conservative treatment only for patients with chronic lymphedema (LE)

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Surgical Intervention — LVA (Lymphovenous Anastomosis) and VLNT (Vascularised Lymph Node Transfer) are two advanced microsurgical techniques that are increasingly implemented in clinical practice in specialized centers and that are already carried out after health insurance application according to local standard of care. They have been studied in their respective mode of action as well as in their effectiveness in treating chronic BCRL (Breast Cancer-Related Lymphedema) in a multitude of mostly observational and single center studies with highly encouraging results. Patients in the interventional arm A will receive surgery with one of the two approaches or a combination of both, in a one or two-stage method, at the discretion of the treating surgeon. Depending on local standards one or both of the above might be combined with liposuction to the affected arm in a one or two-stage approach as well.
  • Procedure: Conservative Complex Physical Decongestion Therapy — Patients randomized to the control arm will receive CDT (Conservative Complex Physical Decongestion Therapy), which currently is considered as the best available standard of care. For this, patients will be referred to one of the dedicated LE (physical/skin) therapy clinics, if not already treated by one, according to their place of residence for continuation of standard conservative therapy. Recommendations to the procedures and treatment frequency of the conservative therapy will be made, but CDT will be done at the discretion of the treating physiotherapist.

Primary Outcomes

  • Change in Quality of Life Questionnaire (Lymph-ICF-UL) (two time assessment at baseline and 15 month after randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-14
Completion: 2036-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 280 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Basel, Switzerland
Collaborators: Swiss National Science Foundation, Rising Tide Foundation, Krebsforschung Schweiz, Bern, Switzerland
Principal Investigators:
  • Elisabeth Kappos, Prof. Dr. (PRINCIPAL_INVESTIGATOR) - University Hospital, Basel, Switzerland
Contact Information
Study Contact:
Elisabeth Kappos, Prof. Dr.
+41 61 328 62 54
elisabeth.kappos@usb.ch
Siba Haykal, MD, PhD.
Yale School of Medicine
Siba Haykal, MD, PhD
Yale School of Medicine
Interventions
  • Procedure: Surgical Intervention — LVA (Lymphovenous Anastomosis) and VLNT (Vascularised Lymph Node Transfer) are two advanced microsurgical techniques that are increasingly implemented in clinical practice in specialized centers and that are already carried out after health insurance application according to local standard of care. They have been studied in their respective mode of action as well as in their effectiveness in treating chronic BCRL (Breast Cancer-Related Lymphedema) in a multitude of mostly observational and single center studies with highly encouraging results. Patients in the interventional arm A will receive surgery with one of the two approaches or a combination of both, in a one or two-stage method, at the discretion of the treating surgeon. Depending on local standards one or both of the above might be combined with liposuction to the affected arm in a one or two-stage approach as well.
  • Procedure: Conservative Complex Physical Decongestion Therapy — Patients randomized to the control arm will receive CDT (Conservative Complex Physical Decongestion Therapy), which currently is considered as the best available standard of care. For this, patients will be referred to one of the dedicated LE (physical/skin) therapy clinics, if not already treated by one, according to their place of residence for continuation of standard conservative therapy. Recommendations to the procedures and treatment frequency of the conservative therapy will be made, but CDT will be done at the discretion of the treating physiotherapist.
Study Locations (36 sites)
Yale School of Medicine, New Haven, Connecticut 06510 United States
Harvard Medical School, Boston, Massachusetts 02115 United States
Washington University School of Medicine in St. Louis, St Louis, Missouri 63110 United States
Mayo Clinic, Rochester, New York 55905 United States
University Clinics St.Pölten, Sankt Pölten, Lower Austria Austria
Krankenhaus Göttlicher Heiland GmbH, Vienna, State of Vienna A-1170 Austria
Brussels University Hospital, Brussels, Jette 1090 Belgium
University of Ghent, Ghent, 9000 Belgium
Hospital Erasto Gaertner, Paraná, Curitiba 80730-001 Brazil
McGill University, Royal Victoria Hospital, Montreal, QC H4A 3J1 Canada
Eligibility Criteria
Inclusion Criteria: * Written informed consent. * Patients ≥ 18 years of age. * Former diagnosis of breast cancer. * Clinical diagnosis of chronic Breast Cancer-Related Lymphedema (BCRL) (persisting for more than 3 months) classified as ≥ Stage 1, according to ISL. * Minimum of 3 months Conservative Complex Physical Decongestion Therapy. * Ability to complete the QoL questionnaires. * Willingness to undergo surgery. Exclusion Criteria: * No indication for lymphatic surgery according to clinical judgment of the treating surgeon (individual reasons will be specifically documented). * Primary congenital Lymphedema or non-BCRL. * Previous surgical BCRL treatment on the side intended for intervention.
Conditions Anxiety Disorder, Depressive Disorder
Phase NA
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Anxiety and depressive disorders, referred to as emotional disorders, have high rates of prevalence, recurrence, and functional impairment. Transdiagnostic psychotherapy targeting shared features of these disorders has recently emerged. Dialectical behavior therapy (DBT) for the transdiagnostic treatment of emotional disorders is a promising approach, as results of preliminary studies for use in a broad range of mental disorders are encouraging. Since there is a lack of research on transdiagnostic psychotherapy in Taiwan, the investigators thus propose this 3-year randomized controlled trial to test the efficacy of a modified DBT for the treatment of transdiagnostic emotional disorders and to further evaluate whether the efficacy of modified DBT differs in the specific emotional disorders. The investigators expect that patients with emotional disorders receiving modified DBT are more likely to improve clinical outcomes, functioning, and quality of life.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Dialectical behavior therapy (DBT) — The modified DBT protocol, developed by the principal investigator and co-investigators, will be offered in an individual therapy format. It consists of 15 weekly individual sessions, each lasting 50-60 minutes. It is made based on the manual, retaining the essence of DBT and remaining dialectically focused. Each session focuses on specific skills within the context of modules.

Primary Outcomes

  • Change of total score of Hamilton Depression Scale-17 item (HAMD-17) (Pretreatment (0 weeks), Posttreatment (20 weeks), 12-week follow-up (32 weeks))
  • Change of total score of Hamilton Anxiety Scale (HAM-A) (Pretreatment (0 weeks), Posttreatment (20 weeks), 12-week follow-up (32 weeks))
  • Change of total score of Clinical Global Impressions-Severity (CGI-S) and Improvement (CGI-I) (Pretreatment (0 weeks), Posttreatment (20 weeks), 12-week follow-up (32 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-01
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mackay Memorial Hospital
Collaborators: National Science and Technology Council
Principal Investigators:
  • Shen-Ing Liu, Ph.D (PRINCIPAL_INVESTIGATOR) - Mackay Memorial Hospital
Contact Information
Study Contact:
Hui-Chun Huang, Ph.D
886-2-28094661
aihch@mmh.org.tw
Hui-Chun Huang, Ph.D
886228094661
aihch@mmh.org.tw
MacKay Memorial Hospital
Interventions
  • Behavioral: Dialectical behavior therapy (DBT) — The modified DBT protocol, developed by the principal investigator and co-investigators, will be offered in an individual therapy format. It consists of 15 weekly individual sessions, each lasting 50-60 minutes. It is made based on the manual, retaining the essence of DBT and remaining dialectically focused. Each session focuses on specific skills within the context of modules.
Study Locations (1 sites)
MacKay Memorial Hospital, Taipei, Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Mandarin Chinese-language proficiency sufficient to complete the study questionnaire 2. A current diagnosis of depressive or anxiety disorder as diagnosed from a SCAN interview Exclusion Criteria: 1. Intellectual disability 2. Substance use disorder in the past three months 3. Bipolar disorder 4. Psychotic disorder 5. Organic brain disorder 6. Acute suicidality or a history of frequent or recent suicide attempts 7. Recent (past six weeks) change in psychiatric medication or unwillingness to maintain a stable dosage of medication during study participation 8. Had received five or more sessions of CBT in the past five years or was unwilling to stop concurrent psychotherapy for an emotional disorder 9. Any mental or physical condition requiring hospital admission 10. Another medical condition likely to prevent participation in the study As we also aim for a naturalistic setting, we do not exclude patients who undergo a medication change during the trial if this is judged necessary or clinically important by the treating clinician. Instead, we include a question about this in the questionnaire to the referring/treating clinician.
Conditions Psychosis, Depression
Phase Not Applicable
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Not only being the mainstay of treatment for schizophrenia spectrum psychotic disorders, antipsychotics, especially the second-generation antipsychotics (SGAs) have also been recommended as augmenting agents for treating depression. Dopaminergic agents, including both dopamine D2/D3 antagonists and dopamine partial D2 agonists, have been effective for treating psychosis and schizophrenia. Amongst all SGAs, those with partial D2 agonistic property are generally acknowledged to have better side-effect profiles with lower incidence of extrapyramidal side-effects, prolactin increase, weight gain, QTc prolongation, and metabolic syndrome, as well as more efficacious in alleviating depressive symptoms. Up-to-date, three SGAs, namely aripiprazole, brexpiprazole and cariprazine, are known to possess such partial D2 agonism. ReSD-HK study is part of the ReSD Asian Study aiming to carefully evaluate a cohort of patients prescribed with brexpiprazole on its efficacy and tolerability as treatment for schizophrenia and/or depression in a real-life clinical setting.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Brexpiprazole — Brexpiprazole as treatment for psychosis and schizophrenia, and/or as augmentation treatment for depressive disorders

Primary Outcomes

  • Change in Brief Psychiatric Rating Scale-24 in 6 months (6 months)
  • Change in Clinical Global Impression in 6 months (6 months)
  • Change in Beck Anxiety Inventory in 6 months (6 months)
  • Change in Beck Depression Inventory in 6 months (6 months)
  • Change in Digital Symbol Substitution Test in 6 months (6 months)
  • Change in World Health Organization Disability Assessment Schedule 2.0 in 6 months (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-07-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dr. Albert Kar-Kin Chung
Collaborators: Otsuka Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Albert KK Chung, MBBS
2255 4486
Chungkka@hku.hk
Albert KK Chung
2255 4486
chungkka@hku.hk
Queen Mary Hospital
Interventions
  • Drug: Brexpiprazole — Brexpiprazole as treatment for psychosis and schizophrenia, and/or as augmentation treatment for depressive disorders
Study Locations (1 sites)
Queen Mary Hospital, Hong Kong, 000000 Hong Kong
Eligibility Criteria
Inclusion Criteria: * Age: 18- 65 years old at the time of enrollment * Able to read and communicate in English and/or Chinese * Able to give informed consent * Has been diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), or International Statistical Classification of Diseases and Related Health Problems 10th revision (ICD-10) to have either Psychotic Disorders (F10-F19.5, F20-23, F25, F32-F33) * is receiving brexpiprazole as treatment for less than 4 weeks at the time of recruitment Exclusion Criteria: * Age \<18 years old * Unable to read English or Chinese * Unable to give informed consent * Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation (ICD-10 F70-73)
Conditions Depression, Bipolar
Phase PHASE4
Enrollment 122
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal is to study the effect of lithium compared to cariprazine in patients with depression in a bipolar disease. The main question it aims to answer is: Difference in change between the two groups from baseline to after 8 weeks treatment on Hamilton Ratings Scale for Depression, 6-item version (HDS-6) Participants will be randomized to treatment with either lithium or cariprazin. * Will meet for interview and ratings 4 times during study period. * In two meetings, there will be made blood samples and ECG. At one meeting also a Urine sample. * Will be contacted for telephone interviews at 6 occasions.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Lithium — The starting dose (day one) of lithium citrate is 12 mmol (one tablet of lithium citrate contains 6 mmol lithium) given once a day before bedtime. On day three the dose is increased to 18 mmol. Dose adjustments are permitted after 7 days in a flexible manner to result in a 12-hour se-lithium between 0.6 and 0.8 mmol/l, aiming for the upper limit at the treating physician's discretion.
  • Drug: Cariprazine — The starting dose for cariprazine is 1.5 mg daily in a single dose, and subsequently, after a minimum of two weeks, the dose can be increased to 3 mg and decreased again to 1.5 mg daily at the treating physician's discretion.

Primary Outcomes

  • Change in Hamilton Depressions scale, version 6 (HDS-6) (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-12-13
Completion: 2028-09-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 122 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aalborg University Hospital
Collaborators: Glostrup University Hospital, Copenhagen, Mental Health Department Odense, University Clinic, Psychiatric Center Copenhagen, Rigshospitalet, Psychiatric Hospital, Hillerod
Principal Investigators:
  • René E. Nielsen, Prof, MD,PhD (PRINCIPAL_INVESTIGATOR) - Psychiatry, Aalborg University Hospital
Contact Information
Study Contact:
Sanne V. Hovgesen, MD
+45 25487706
sanne.hovgesen@rn.dk
Simon Johnsen, MsN
+45 50589034
simonjohnsen@rn.dk
Sanne V. Hovgesen, MD
+45 29217805
sanne.hovgesen@rn.dk
Aalborg University Hospital
Interventions
  • Drug: Lithium — The starting dose (day one) of lithium citrate is 12 mmol (one tablet of lithium citrate contains 6 mmol lithium) given once a day before bedtime. On day three the dose is increased to 18 mmol. Dose adjustments are permitted after 7 days in a flexible manner to result in a 12-hour se-lithium between 0.6 and 0.8 mmol/l, aiming for the upper limit at the treating physician's discretion.
  • Drug: Cariprazine — The starting dose for cariprazine is 1.5 mg daily in a single dose, and subsequently, after a minimum of two weeks, the dose can be increased to 3 mg and decreased again to 1.5 mg daily at the treating physician's discretion.
Study Locations (1 sites)
Aalborg University Hospital, Aalborg, 9000 Denmark
Eligibility Criteria
Inclusion Criteria: * A diagnosis of bipolar disorder, type 1 or type 2, and a current episode of depression according to DSM-5 * Severity of depression: A score of at least 21 on the self-reported Major Depression Inventory (MDI). * No start or dose increase of psychotropic medication (except for benzodiazepines and benzodiazepine-like drugs (zopiclone, zolpidem, and melatonin)) in the two weeks prior to inclusion. * No new start of formalized psychotherapy sessions, excluding psychoeducation, during the 4 weeks prior to inclusion. * Age criteria: Subjects must be at least 18 years old and below 65 at the time of randomization. * The duration of the current depressive episode must be between 4 and 52 weeks as judged by the investigator at the time of randomization. * Clinical uncertainty regarding which of the alternatives, cariprazine and lithium, would be the better choice in the specific case. * Female participants should be sterile or non-fertile or, in case of being fertile, they must have a negative pregnancy test AND use safe anticonception. * Signed document of informed consent. Exclusion Criteria: * Prior or ongoing acute treatment of a depressive episode lasting \> 14 days with either lithium or cariprazine as judged by the investigator. * ECT within the current depressive episode. * A score of MAS \> 6. * A diagnosis of dementia. * High risk of non-adherence at the investigator's discretion. * Not understanding the Danish language as judged by the investigator * Psychiatric coercion in the form of forced admission or detainment OR sentence to forensic psychiatric care. * Presence of clinically relevant delusions, hallucinations or other psychotic symptoms as judged by the investigator. * Suicidality according to C-SSRS with a positive response to question 4 or 5 or upon investigator's discretion. * Medical conditions like cancer, kidney failure, epilepsy, deep brain stimulation device, or other medical conditions interfering with study the outcome and safety as judged by investigator's discretion. * Current harmful use or dependency of alcohol or drugs according to DSM-5. * Known allergy to any of the substances in the study medication.
Conditions Renovascular Hypertension, Renovascular ...
Phase NA
Enrollment 80
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to document a beneficial effect of percutaneous transluminal renal angioplasty (PTRA) of atherosclerotic renal artery stenosis in high-risk patients selected according to the criteria used in the DAN-PTRA study. The main questions the trial aims to answer are if renal artery stenting compared with optimal medical treatment alone has beneficial effects on: * Blood pressure * Kidney function * Hospitalizations for heart failure

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Optimal medical therapy (OMT) — Optimal medical therapy, including maximally tolerated renin-angiotensin system blockade with either an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker.
  • Diagnostic Test: Catheter-based angiography — Catheter-based angiography performed in accordance with the study protocol.
  • Diagnostic Test: Measurement of translesional pressure gradients — Measurement of translesional pressure gradients performed in accordance with the study protocol.
  • Procedure: Renal artery stenting — Renal artery stenting performed in accordance with the study protocol.
  • Procedure: Sham (No Treatment) — Sham procedure performed in accordance with the study protocol.

Primary Outcomes

  • Change in 24-hour ambulatory systolic blood pressure (Baseline and 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-26
Completion: 2027-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Aarhus
Collaborators: Aarhus University Hospital, Rigshospitalet, Denmark, Odense University Hospital, Aalborg University Hospital, Gødstrup Hospital, Holbaek Sygehus, Amsterdam UMC, The Novo Nordic Foundation, The Augustinus Foundation, Denmark.
Principal Investigators:
  • Mark Reinhard, MD, PhD (PRINCIPAL_INVESTIGATOR) - Aarhus University Hospital
Contact Information
Study Contact:
Sebastian Nielsen, MD
+45 23100484
sebane@rm.dk
Mark Reinhard, MD, PhD
+45 40460321
m.reinhard@dadlnet.dk
Sebastian Nielsen, MD
sebane@rm.dk
Aarhus University Hospital
Interventions
  • Drug: Optimal medical therapy (OMT) — Optimal medical therapy, including maximally tolerated renin-angiotensin system blockade with either an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker.
  • Diagnostic Test: Catheter-based angiography — Catheter-based angiography performed in accordance with the study protocol.
  • Diagnostic Test: Measurement of translesional pressure gradients — Measurement of translesional pressure gradients performed in accordance with the study protocol.
  • Procedure: Renal artery stenting — Renal artery stenting performed in accordance with the study protocol.
  • Procedure: Sham (No Treatment) — Sham procedure performed in accordance with the study protocol.
Study Locations (3 sites)
Aarhus University Hospital, Aarhus N, 8200 Denmark
Rigshospitalet, Copenhagen, 2100 Denmark
Odense University Hospital, Odense C, 5000 Denmark
Eligibility Criteria
Inclusion Criteria: 1. One or more severe atherosclerotic renal artery stenoses defined as a stenosis ≥70% by catheter-based angiography. 2. In addition, at least one of the following high-risk clinical syndromes: 1. Resistant hypertension with average 24-hour ambulatory systolic blood pressure ≥150 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses. 2. Rapidly declining kidney function with a reduction in estimated GFR of \>5 mL/min per 1.73m2 per year and average 24-hour ambulatory systolic blood pressure ≥140 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses. 3. Hospital admissions with acute decompensated heart failure (≥2 hospitalizations for heart failure or ≥1 hospitalizations for sudden, "flash" pulmonary edema) with no obvious explanations such as nonadherence, left ventricular ejection fraction \<40%, or valvular heart disease and average 24-hour ambulatory systolic blood pressure ≥140 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses. All 24-hour ambulatory blood pressure monitorings are performed after nurse-administered medication. Exclusion Criteria: * Unable to provide informed consent. * Treatment-resistant heart failure episodes presumed caused by renovascular disease. * Rapidly declining kidney function/acute kidney failure approaching the need for dialysis presumed caused by renovascular disease. * Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis known to be present prior to randomization. * Pregnancy or unknown pregnancy status in female of childbearing potential. * Kidney size \<7 cm (pole to pole length) supplied by target vessel. * Previous kidney transplant. * Previous PTRA treatment. * Presence of a renal artery stenosis not amenable for treatment with a stent. Patients who are not eligible for randomization but treated with renal artery stenting outside the protocol are followed according to the DAN-PTRAII protocol in order to account for all PTRA treatments performed in Denmark in the study period. Patients treated with renal artery stenting without randomization in the study period include patients with: 1. Treatment-resistant heart failure episodes presumed caused by renovascular disease. 2. Rapidly declining kidney function/acute kidney failure approaching the need for dialysis presumed caused by renovascular disease. 3. At least one of the listed high-risk clinical syndromes AND one or more significant atherosclerotic renal artery stenoses defined as a stenosis of 50-69% by catheter-based angiography with: * a mean translesional gradient of ≥10 mm Hg, or * a systolic translesional gradient of ≥20 mm Hg, or * a renal fractional flow reserve (Pd/Pa) of ≤0.8
Conditions Glaucoma, Open-Angle
Phase PHASE3
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the efficacy of citicoline eye drops 2% in reducing visual field deterioration in patients with progressing OAG treated according to best clinical practice. Secondary objectives are assessing the effect of citicoline eye drops 2% on changes in structural parameters measured by Spectral Domain Optical Coherence Tomography (SD-OCT) and evaluating the safety of citicoline eye drops 2%

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Citicoline eye drops 2% — Eye drops containing Citicoline 2%
  • Drug: Placebo — Eye drops containing placebo matching product

Primary Outcomes

  • Progression of visual field damage (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-12-11
Completion: 2027-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Omikron Italia S.r.l.
Collaborators: OPIS Spain
Contact Information
Study Contact:
Carla Russo
+39 06 80693572
c.russo@omikronitalia.it
Luca Rossetti, Prof.
00390281844556
luca.rossetti@unimi.it
Presidio Ospedale San Paolo
Interventions
  • Drug: Citicoline eye drops 2% — Eye drops containing Citicoline 2%
  • Drug: Placebo — Eye drops containing placebo matching product
Study Locations (1 sites)
Presidio Ospedale San Paolo, Milan, MI 20142 Italy
Eligibility Criteria
Inclusion Criteria: 1. Signed written informed consent. 2. Age ≥ 18 years. 3. Eyes with OAG, Pseudoexfoliation and pigmentary glaucoma will be included. 4. Best Corrected Visual Acuity (BCVA) ≥ 0.5 for the study eye. 5. Controlled IOP (≤ 18 mmHg, average of the last 3 measurements in the clinic) in the study eye. 6. Visual field MD not worse than -12 dB at the latest assessment in the clinic for the study eye. 7. Deteriorating MD at a rate between -0.5 dB/year and -1.0 dB/year, estimated from the latest VF tests collected in the clinic (at least 4) over a period during which incisional glaucoma surgery was not performed. Combinations of SITA Standard and Fast strategies (but not SITA Faster) is admissible. Patients who reach the desired minimum number of tests (4) with a mixture of SITA Standard/Fast and SITA Faster tests will need to perform additional replacement tests according to the prevalent strategy used in their series of VF (i.e. additional SITA Standard/Fast tests if ≤ 2 tests were SITA Faster; additional SITA Faster if \> 2 tests were SITA Faster). 8. Glaucoma definition will be based on VF damage (24-2, any SITA strategy) and spatially congruent glaucomatous changes at the ONH. If both eyes are eligible, the eye with the better MD will be chosen as the study eye. 9. Women of childbearing potential willing to use an appropriate method of contraception. Exclusion Criteria: 1. Cataract in the study eye which, in the opinion of the clinician, may require cataract surgery within the next three years. 2. Only-eye patients (visual acuity \< 0.1 decimals in one eye or more than two paracentral VF locations with a sensitivity of \< 10 dB). 3. Known intolerance or allergy to any of the components in the eye drops. 4. Diode laser treatment or glaucoma surgery in the past 2 years or cataract surgery within the last 6 months in the study eye. 5. Eyes with any type of glaucoma other than primary, pseudoexfoliative or pigmentary OAG. 6. Patients with other ocular or systemic comorbidities that, in the opinion of the Investigator, might affect the VF or the execution of the test. 7. Patients already on topical or systemic citicoline treatment. 8. Patients taking other systemic or topical potential neuroprotectors competing with citicoline eye drops 2% (a list will be provided) unwilling to suspend these treatments and undergo a washout period of 6 months prior to the study. 9. Patients unable to perform reliable VF tests, based on the assessment of the last 4 available 24-2 Humphrey Field Analyzer (HFA) VF tests performed in the clinic with a false positive rate (FP) ≤ 15%. 10. Pregnant and nursing patients.
Conditions Postpartum Depression
Phase NA
Enrollment 2320
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Reach Out, Stand Strong, Essentials for New Mothers (ROSE) program is an evidence-based intervention that prevents half of cases of postpartum depression and was one of two interventions recommended by the US Preventive Services Task Force in 2019. All effectiveness trials of ROSE and of the other recommended PPD prevention intervention included only low-income women a single risk factor that doubles incidence of PPD. Thus, the existing evidence base for PPD prevention consists primarily of women at increased risk for PPD. Based on data from the PIs' current implementation study of ROSE, many healthcare and community agencies in this implementation trial (78%) find it is more feasible for them to provide or offer ROSE to every woman as part of their standard workflow, than it is to create a screening and referral process for at risk women. In addition to being more feasible for agencies, universal prevention may also be advantageous because the cost of a screening false negative (resulting in a preventable case of PPD; $32,000) far exceeds the cost of ROSE delivery ($50-$300/woman). Effectiveness of ROSE among low-income women at risk for PPD is known (ROSE prevents \~50% of PPD cases). To inform a recommendation about using ROSE as universal vs. selective or indicated prevention, we need to determine the effectiveness of ROSE among general populations of women, including women screening negative for PPD risk. Thus, this project will assess ROSE effectiveness across PPD risk levels and across prevention approaches in a sample of 2,320 women from a large regional health system (based in Detroit, MI). Each proposed aim gathers a piece of information missing that is needed to guide decision-making about ROSE as universal prevention. We will assess ROSE as universal, selective, and indicated prevention in terms of: (1) ROSE effectiveness relative to a control for each prevention approach in preventing PPD and improving functioning; (2) cost outcome, (3) equity and (4) scalability of each prevention approach; and (5) mechanisms of ROSE effects across PPD risk levels. We will integrate results to advise about ROSE as universal prevention. This definitive PPD prevention trial will show how best to get an evidence-based program to those who need it in settings where they receive perinatal care by addressing a pragmatic and novel question (should ROSE be universal prevention?) and by examining equity and cost-outcome of universal vs. other prevention approaches.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) — Evidence-based 5 session psychosocial intervention that has been found to prevent \~50% of postpartum depression among low-income, at risk women.
  • Behavioral: Enhanced Care as Usual (CAU) — Usual care at the study site does not include postpartum depression prevention. Instead, HFHS clinics try to screen for PPD that has already occurred and refer women for mental health care. Screening for existing PPD at these clinics primarily relies on the EPDS (10+), Perinatal women who score 10+ on the EPDS are referred for mental health services. Services received depends on follow-up, severity, and the mental health wait list. Our study will exclude women meeting criteria for likely current major depressive episode at baseline and assist them in obtaining mental health care. Enhanced CAU consists of usual care + monitoring and emergency referral, as is required to fulfill ethical obligations to trial participants.

Primary Outcomes

  • SCID-5 Major Depressive Episode (through 6 months after birth)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 2320 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Michigan State University
Collaborators: Pacific Institute for Research and Evaluation, Henry Ford Health System, Butler Hospital
Principal Investigators:
  • Jennifer E Johnson, PhD (PRINCIPAL_INVESTIGATOR) - Michigan State University
  • Caron Zlotnick, PhD (PRINCIPAL_INVESTIGATOR) - Butler Hospital
Contact Information
Study Contact:
Jennifer E Johnson, PhD
810-600-5669
jjohns@msu.edu
Caron Zlotnick, PhD
401-474-3332
CZlotnick@Butler.org
Jennifer Johnson, PhD
jjohns@msu.edu
Michigan State University
Interventions
  • Behavioral: ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) — Evidence-based 5 session psychosocial intervention that has been found to prevent \~50% of postpartum depression among low-income, at risk women.
  • Behavioral: Enhanced Care as Usual (CAU) — Usual care at the study site does not include postpartum depression prevention. Instead, HFHS clinics try to screen for PPD that has already occurred and refer women for mental health care. Screening for existing PPD at these clinics primarily relies on the EPDS (10+), Perinatal women who score 10+ on the EPDS are referred for mental health services. Services received depends on follow-up, severity, and the mental health wait list. Our study will exclude women meeting criteria for likely current major depressive episode at baseline and assist them in obtaining mental health care. Enhanced CAU consists of usual care + monitoring and emergency referral, as is required to fulfill ethical obligations to trial participants.
Study Locations (1 sites)
Michigan State University, Flint, Michigan 48502 United States
Eligibility Criteria
Inclusion Criteria: 1. Is aged 18 or older 2. Is receiving prenatal services within the U.S 3. Is between 12-32 weeks pregnant 4. Speaks and understand English well enough to understand questionnaires when they are read aloud 5. Has access to a telephone through owning one, a relative/friend, or an agency 6. Is willing and able to provide the name and contact information of at least two locator persons Exclusion Criteria: 1. Has a current major depressive episode 2. Has current or past diagnosis of a bipolar disorder or a psychotic disorder
Conditions Clear Cell Renal Cell Cancer (ccRCC), Pa...
Phase PHASE1, PHASE2
Enrollment 270
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of \[68Ga\]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC); Part B: is to determine the recommended phase 2 dose (RP2D) \[maximum tolerated dose (MTD) or lower dose\] for \[177Lu\]Lu-DPI-4452 for each tumor type such as ccRCC, PDAC, CRC, and urothelial carcinoma (UC); Part C: is to evaluate the preliminary antitumor activity of \[177Lu\]Lu-DPI-4452 as monotherapy for each tumor type such as ccRCC, PDAC, CRC, and UC; Part D: is to assess the diagnostic concordance between \[68Ga\]Ga-DPI-4452 Positron Emission Tomography (PET) and the histopathology result of the Indeterminate Renal Mass (IDRM); Part E: is to assess \[68Ga\]Ga-DPI-4452 uptake in each tumour type such as UC, muscle invasive bladder cancer (MIBC), head and neck cancer (H\&N), triple negative breast cancer (TNBC), squamous non-small cell lung cancer (NSCLC), and any other tumor with locally confirmed carbonic anhydrase (CA) IX expression except ccRCC, CRC and PDAC.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: [68Ga]Ga-DPI-4452 — \[68Ga\]Ga-DPI-4452, administered as IV injection.
  • Drug: [177Lu]Lu-DPI-4452 — \[177Lu\]Lu-DPI-4452, administered as IV infusion.

Primary Outcomes

  • Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Up to Day 7)
  • Part B: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) (Cycle 1(each cycle = 28 or 42 days depending on every 4 weeks or 6 weeks dosing schedule))
  • Part C: Objective Response Rate (ORR) (Up to 81 months)
  • Part D: Concordance Between [68Ga]Ga-DPI-4452 Uptake by PET Imaging and Assessment of Histological Characteristics of IDRM (Day 1)
  • Part E: Radiotracer Uptake at Lesion Level Identified by PET Imaging (Day 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-03-14
Completion: 2029-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 270 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lumara Bio Oncologics GmbH
Contact Information
Study Contact:
Lumara Bio Oncologics GmbH
(+49) 89 329898 66000
info-itm91_94-phase1_2@itm-radiopharma.com
Interventions
  • Drug: [68Ga]Ga-DPI-4452 — \[68Ga\]Ga-DPI-4452, administered as IV injection.
  • Drug: [177Lu]Lu-DPI-4452 — \[177Lu\]Lu-DPI-4452, administered as IV infusion.
Study Locations (10 sites)
Peter MacCallum Cancer Centre, Melbourne, VIC 3000 Australia
UNSW Sydney, St Vincent's Hospital Sydney, Sydney, NSW 2010 Australia
Centre Jean Perrin, Clermont-Ferrand, 63011 France
Centre Georges François Leclerc, Dijon, 21079 France
CHU de Grenoble-Alpes, Boulevard de la Chantourne, Grenoble, 38043 France
Centre Léon Bérard, Lyon, 69373 France
AP-HM - Hopital de la Timone, Marseille, 13005 France
CHU de Nantes, Nantes, 44093 France
IUCT - Oncopole, Toulouse, 31100 France
CHRU de Nancy - Hopitaux de Brabois, Vandœuvre-lès-Nancy, 54511 France
Eligibility Criteria
Inclusion Criteria: Part A, B, and C: * Written informed consent, dated and signed by the patient prior to any study-specific procedure. * Part B and C are not conducted in the United States of America. * Has histologically or cytologically confirmed, unresectable locally advanced or metastatic solid tumors of: * Clear cell renal cell cancer (ccRCC) - participants must have received at least one line containing Tyrosine kinase inhibitor (TKI) treatment and at least one line containing immune checkpoint inhibitor treatment in metastatic setting, meaning at least two lines of treatment in metastatic setting. * Pancreatic ductal adenocarcinoma (PDAC) - participants must have received at least one line of platinum- and/or gemcitabine-based regimen. * Colorectal cancer (CRC) - participants must have received at least one line of FOLFIRINOX or FOLFOX/FOLFIRI in two lines in combination with anti-Vascular Endothelial Growth Factor (VEGF) or anti-Epidermal Growth Factor Receptor (EGFR). * Participants with CRC or PDAC: availability of fresh biopsy, OR an archival biopsy/surgical specimen of the tumor (preferably, taken after last prior line of therapy). * For Part B and C only: Urothelial cancer (UC) patients must have received all available standard of care if eligible, including one line of platinum-based chemotherapy, enfortumab vedotin and pembrolizumab. * Presence of at least 1 non-irradiated tumor lesion detected at conventional imaging (computed tomography / magnetic resonance imaging (CT/MRI)) documented within 4 weeks prior to the \[68Ga\]Ga-DPI-4452 administration. * Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1. Part D: Participants with imaging evidence of a single indeterminate renal mass (IDRM) of ≤ 7 cm in largest diameter (tumor stage cT1) on any conventional diagnostic imaging technique, suspicious for ccRCC and planned for total or partial nephrectomy, or interventional diagnostic (cystoscopy and retrograde pyelography or biopsy) within 90 days from planned \[68Ga\]Ga-DPI-4452 administration. Part E: Regardless of lines of treatment, participants with histologically or cytologically confirmed progressive, unresectable locally advanced or metastatic solid tumors of * UC, including MIBC * H\&N cancer * TNBC * Squamous NSCLC * Any other indication with confirmed carbonic anhydrase IX (CA IX) expression excluding ccRCC, PDAC and CRC, upon Sponsor agreement. Presence of at least 1 non-irradiated tumor lesion detected at conventional imaging (CT/MRI) documented within 4 weeks prior to the \[68Ga\]Ga-DPI-4452 administration (for scans dated more than 4 weeks prior to D1, the Sponsor should be contacted to assess conventional imaging suitability) Exclusion Criteria: * Any major surgery within 12 weeks before enrolment. * Inability to stay in the scanner bed with the arms resting out of the thoracic and abdominal fields (i.e., arms alongside the body or raised arm position) for the duration of the scan. Part A: * Has known hypersensitivity to the active substance, to any of the excipients of the DPI-4452, or to radiographic contrast agents. * Bladder outflow obstruction or unmanageable urinary incontinence. * Participants who have not had resolution of clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for laboratory parameters specified above, Grade 2 alopecia, and/or stable Grade 2 sensory neuropathy, according to National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI-CTCAE\]). * Administration of a radiopharmaceutical within a period corresponding to 10 half-lives of the radionuclide used prior to injection of \[68Ga\]Ga-DPI-4452. * Previous Carbonic anhydrase (CA) IX-targeting treatment. * Prior external beam radiation therapy (EBRT) to more than 25% of the bone marrow, as judged by the Investigator. Part B and Part C: * Known hypersensitivity to the active substance, to any of the excipients of the DPI-4452, or to radiographic contrast agents. * Bladder outflow obstruction or unmanageable urinary incontinence. * Participants who have not had resolution of clinically significant toxic effects of prior systemic cancer therapy, surgery, active clinically significant cardiac disease, or radiotherapy to Grade ≤1 (except for laboratory parameters specified above, Grade 2 alopecia, or stable Grade 2 sensory neuropathy, according to NCI-CTCAE). * Administration of a radiopharmaceutical with therapeutic intent within a period of 6 months prior to injection of \[68Ga\]Ga-DPI-4452. * Any previous CA IX-targeting treatment for non-oncological indication within 3 months prior to the \[177Lu\]Lu-DPI-4452 infusion; any previous CA IX-targeting treatment for any oncological indication. * Participants who received any systemic antineoplastic therapy for the underlying disease and/or other investigational agents within a period which is ≤5 half-lives or ≤4 weeks (whichever is shorter). * Inflammatory bowel disease (e.g Crohn's disease, ulcerative colitis, etc). Part D: * Known hypersensitivity to the active substance, to any of the excipients of the DPI-4452, or to radiographic contrast agents. * Any previous CA IX-targeting treatment within 3 months prior to the \[68Ga\]Ga-DPI-4452 injection. * Administration of a radiopharmaceutical within a period corresponding to 10 half-lives of the radionuclide used prior to injection of \[68Ga\]Ga-DPI-4452. * Malignant disease, other than that being treated in this study. Exceptions include the following: malignancies that were treated curatively and have not recurred within 2 years prior to screening; treated basal cell or localized squamous skin carcinomas, localized or low grade (e.g., Gleason 3+3 or 3+4 with low prostate specific antigen) prostate cancer, superficial (non-muscle invasive) urothelial cancer, localized thyroid gland microcarcinoma, other in-situ carcinoma, or other malignancy for which participants are not on active antineoplastic therapy. * Ongoing treatment with sulfonamides and/or coumarin derivatives (e.g., acenocoumarol, warfarin, phenprocoumon) within 2 weeks (or 5 half-lives, whichever is longer) prior to the \[68Ga\]Ga-DPI-4452 injection. Part E: * Known hypersensitivity to the active substance, to any of the excipients of the DPI-4452, or to radiographic contrast agents. * Administration of a radiopharmaceutical within a period corresponding to 10 half-lives of the radionuclide used prior to injection of \[68Ga\]Ga-DPI-4452. * Any previous CA IX-targeting treatment within 3 months prior to \[68Ga\]Ga-DPI-4452 injection. * EBRT to more than 25% of the bone marrow, as judged by the Investigator. * Malignant disease, other than that being treated in this study. Exceptions include the following: malignancies that were treated curatively and have not recurred within 2 years prior to screening; treated basal cell or localized squamous skin carcinomas, localized or low grade (e.g., Gleason 3+3 or 3+4 with low prostate specific antigen) prostate cancer, superficial (non-muscle invasive) urothelial cancer, localized thyroid gland microcarcinoma, other in-situ carcinoma, or other malignancy for which participants are not on active antineoplastic therapy. Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.
Conditions Anatomic Stage IV Breast Cancer AJCC v8,...
Phase NA
Enrollment 5
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial evaluates the safety and feasibility of tumor treating fields (TTF) in the treatment of spinal leptomeningeal disease in patients with breast or lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Patients wear the portable Novo TTF-200T device that produces electric fields to target areas on the body to stop the growth of tumor cells. The information from this study will help researchers develop a better treatment for leptomeningeal metastases in the future.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Digital Photography — Digital photographs taken of array placement
  • Procedure: Lumbar Puncture — Undergo LP
  • Procedure: Magnetic Resonance Imaging — Undergo MRI
  • Device: Medical Device Usage and Evaluation — Transducer arrays applied and wear NovoTTF-200T
  • Procedure: Biospecimen Collection — Undergo collection of cerebrospinal fluid (CSF) during screening if no CSF testing for malignancy has been done previously

Primary Outcomes

  • Incidence of significant toxicity of tumor treating fields (TTFs) (Up to 3 years)
  • Feasibility of TTFs - completion of at least 28 days of TTF therapy (Up to 28 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-07
Completion: 2027-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 5 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Wendy J. Sherman, MD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Mayo Clinic in Florida
Wendy J. Sherman, MD
Mayo Clinic in Florida
Interventions
  • Other: Digital Photography — Digital photographs taken of array placement
  • Procedure: Lumbar Puncture — Undergo LP
  • Procedure: Magnetic Resonance Imaging — Undergo MRI
  • Device: Medical Device Usage and Evaluation — Transducer arrays applied and wear NovoTTF-200T
  • Procedure: Biospecimen Collection — Undergo collection of cerebrospinal fluid (CSF) during screening if no CSF testing for malignancy has been done previously
Study Locations (1 sites)
Mayo Clinic in Florida, Jacksonville, Florida 32224-9980 United States
Eligibility Criteria
Inclusion Criteria: * Age \>= 18 * Prior tissue diagnosis of breast cancer or lung cancer * Confirmed diagnosis of leptomeningeal metastases (LM) with positive cerebrospinal fluid (CSF) cytology for malignancy and meningeal enhancement (type 1A, 1B, and 1C) * Radiographic evidence on MRI of leptomeningeal enhancement within the cervical, thoracic or lumbar spine on spinal MRI * Life expectancy of at least 6 weeks * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2, or 3 * Recovery from any neurotoxic effects of prior therapy * Platelet count greater than 25 x 10\^9/L * Absolute neutrophil count (ANC) greater than 0.5 x 10\^9/L * Patients must have adequate liver function, total bilirubin \< 2.5 mg/dL, unless elevated total bilirubin is due to elevated indirect bilirubin from known Gilbert's disease, aspartate aminotransferase (AST) =\< 3.5 times upper limits of normal; adequate renal function \[calculated estimated glomerular filtration rate (eGFR) \>= 30 mL/min/ body surface area (BSA)\] * Patients or legal medical representative must provide written informed consent * Patients must have suitable body habitus for placement of transducer arrays * Patients must be willing to wear the device for at least 18 hours a day (averaged over monthly) * Patients must be willing to return for the scheduled evaluations and perform the required assessments * Patients are without other disease or situation which would significantly compromise adequate assessment of safety and feasibility of the TTF * Patient willing to start a study treatment with TTF =\< 14 days from registration Exclusion Criteria: * Concomitant therapy: * Must not be receiving concurrent high-dose methotrexate (\>= 3 g/m\^2), high dose thiotepa, or high-dose cytarabine (\>= 3 g/m\^2). Any other systemic chemotherapy, targeted treatment, hormonal or immunotherapy directed at the primary systemic malignancy is permitted * Must not have received radiation therapy (RT) to the brain or spinal cord within 2 weeks of initiation of TTF * Must be at least 1 week from cessation of any prior intrathecal chemotherapy * Women of childbearing age who are pregnant or lactating. (Male and female patients who are fertile must be willing to use an effective means of birth control to avoid pregnancy) * Patients with uncontrolled or untreated infection including active hepatitis, and human immunodeficiency virus (HIV) * Patients receiving any other investigational agents and must not have received any other investigational agent within 14 days prior to registration. The 14-day period should be extended if the investigational agent is known to have delayed toxicity * Patients known to be allergic to the hydrophilic gel utilized for transducer attachment * Patients with surgical hardware within the planned area of treatment in the spine (e.g., titanium rods, screws, fixation devices)
Conditions Hypertension, Pregnancy Induced, Hyperte...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cardiovascular disease is the leading cause of death among women in the United States, and women with hypertensive disorders of pregnancy have a 2-fold higher risk for cardiovascular disease later in life compared to women with uncomplicated pregnancies. This research investigates a patient-centered intervention during the postpartum period to promote engagement in cardiovascular preventive care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Decision aid — A decision aid will be developed based on qualitative data from Aim 1 and iterative refinement with input from stakeholders from Aim 2. Anticipated content includes: 1) information about cardiovascular risk following hypertensive disorders of pregnancy; 2) goal-setting exercises for blood pressure, weight management, glucose control, physical activity, and smoking cessation; 3) self-care steps to achieve management targets; 4) values clarification exercises to identify values related to cardiovascular risk management and identify priority areas for focus and improvement; and 5) discussion of how to communicate questions and goals of treatment to their provider.

Primary Outcomes

  • Decisional conflict (6-8 weeks postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-15
Completion: 2027-08
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Utah
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Contact Information
Study Contact:
Lauren Theilen, MD
801-581-8425
lauren.theilen@hsc.utah.edu
Lauren Theilen, MD
801-581-8425
lauren.theilen@hsc.utah.edu
University of Utah Hospital
Interventions
  • Other: Decision aid — A decision aid will be developed based on qualitative data from Aim 1 and iterative refinement with input from stakeholders from Aim 2. Anticipated content includes: 1) information about cardiovascular risk following hypertensive disorders of pregnancy; 2) goal-setting exercises for blood pressure, weight management, glucose control, physical activity, and smoking cessation; 3) self-care steps to achieve management targets; 4) values clarification exercises to identify values related to cardiovascular risk management and identify priority areas for focus and improvement; and 5) discussion of how to communicate questions and goals of treatment to their provider.
Study Locations (1 sites)
University of Utah Hospital, Salt Lake City, Utah 84132 United States
Eligibility Criteria
Inclusion Criteria: * Delivered a pregnancy complicated by a hypertensive disorder of pregnancy at the University of Utah during the current hospital admission * Ability to speak and read English or Spanish * Written informed consent obtained Exclusion Criteria: * Cardiovascular disease diagnosis (history of peripheral artery disease, stroke, or myocardial infarction) * Impairment of cognitive function or vision that prohibits communication and/or reading the decision aid.